HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pandit-Taskar, N. Articles by Divgi, C. R. Search for Related Content PubMed PubMed Citation Articles by Pandit-Taskar, N. Articles by Divgi, C. R.

Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases^*

Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Bone metastasis occurs as a result of a complex pathophysiologic process between host and tumor cells leading to cellular invasion, migration adhesion, and stimulation of osteoclastic and osteoblastic activity. The process is mediated by parathyroid hormones, cytokines, and tumor-derived factors. Several sequelae occur as a result of osseous metastases and resulting bone pain can lead to significant debilitation. Pain associated with osseous metastasis is thought to be distinct from neuropathic or inflammatory pain. Several mechanisms—such as invasion of tumor cells, spinal cord astrogliosis, and sensitization of nervous system—have been postulated to cause pain. Pharmaceutical therapy of bone pain includes nonsteroidal analgesics and opiates. These drugs are associated with side effects, and tolerance to these agents necessitates treatment with other modalities. Bisphosphonates act by inhibiting osteoclast-mediated resorption and have been increasingly used in treatment of painful bone metastasis. While external beam radiation therapy remains the mainstay of pain palliation of solitary lesions, bone-seeking radiopharmaceuticals have entered the therapeutic armamentarium for the treatment of multiple painful osseous lesions. ³²P has been used for >3 decades in the treatment of multiple osseous metastases. The myelosuppression caused by this agent has led to the development of other bone-seeking radiopharmaceuticals, including ⁸⁹SrCl, ¹⁵³Sm-ethylenediaminetetramethylene phosphonic acid (¹⁵³Sm-EDTMP), ^179mSnCl, and ¹⁶⁶Ho-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonate (¹⁶⁶Ho-DOTMP). ⁸⁹Sr is a bone-seeking radionuclide, whereas ¹⁵³Sm-EDTMP is a bone-seeking tetraphosphonate; both have been approved by the Food and Drug Administration for the treatment of painful osseous metastases. While both agents have been shown to have efficacy in the treatment of painful osseous metastases from prostate cancer, they may also have utility in the treatment of painful osseous metastases from breast cancer and perhaps from non-small cell lung cancer. This article illustrates the salient features of these radiopharmaceuticals, including the approved dose, method of administration, and indications for use. We conclude with recommended guidelines for therapy and follow-up.

Key Words: radiopharmaceutical therapy • bone-seeking radiopharmaceuticals • bone pain • osseous metastases

Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  

This article has been cited by other articles:

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				O. S. Bruland, S. Nilsson, D. R. Fisher, and R. H. Larsen High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the {alpha}-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clin. Cancer Res., October 15, 2006; 12(20): 6250s - 6257s. [Abstract] [Full Text] [PDF]

				W.-C. Huang, D. Wu, Z. Xie, H. E. Zhau, T. Nomura, M. Zayzafoon, J. Pohl, C.-L. Hsieh, M. N. Weitzmann, M. C. Farach-Carson, et al. {beta}2-Microglobulin Is a Signaling and Growth-Promoting Factor for Human Prostate Cancer Bone Metastasis. Cancer Res., September 15, 2006; 66(18): 9108 - 9116. [Abstract] [Full Text] [PDF]